GALT (Galectin Therapeutics Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by GALT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Richard E Uihlein | Director | M | — | — |
| 2026-07-16 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2026-06-25 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2026-05-28 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2026-03-17 | Henry Brem | Director | A | — | — |
| 2026-02-09 | KARY ELDRED | Director | Buy | — | — |
| 2026-01-22 | JOEL LEWIS | President and CEO | A | — | — |
| 2026-01-21 | Elissa J. Schwartz | Director | A | — | — |
| 2026-01-21 | KARY ELDRED | Director | A | — | — |
| 2026-01-21 | BENJAMIN CARSON SR | Director | A | — | — |
| 2026-01-21 | GILBERT S OMENN | Director | A | — | — |
| 2026-01-21 | KEVIN D FREEMAN | Director | A | — | — |
| 2026-01-21 | GILBERT F AMELIO | Director | A | — | — |
| 2026-01-21 | Richard A. Zordani Jr. | Director | A | — | — |
| 2026-01-21 | JOEL LEWIS | President and CEO | A | — | — |
| 2026-01-21 | JACK W CALLICUTT | Chief Financial Officer | A | — | — |
| 2026-01-21 | Richard E Uihlein | Director | A | — | — |
| 2026-01-21 | Harold H. Shlevin | Director | A | — | — |
| 2026-01-21 | Khurram Jamil | Chief Medical Officer | A | — | — |
| 2026-01-13 | JOEL LEWIS | President and CEO | — | — | — |
| 2026-01-06 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2026-01-06 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| 2026-01-05 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2025-12-23 | KARY ELDRED | Director | Buy | — | — |
| 2025-12-23 | KEVIN D FREEMAN | Director | Buy | — | — |
| 2025-12-23 | KEVIN D FREEMAN | Director | Buy | — | — |
| 2025-12-23 | KARY ELDRED | Director | Buy | — | — |
| 2025-12-23 | KEVIN D FREEMAN | Director | Buy | — | — |
| 2025-12-19 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-12-19 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2025-12-19 | Harold H. Shlevin | Director | MIXED | — | — |
| 2025-12-18 | 10X Fund, L.P. | 10%+ Owner | MIXED | — | — |
| 2025-12-16 | Harold H. Shlevin | Director | MIXED | — | — |
| 2025-12-10 | Harold H. Shlevin | Director | MIXED | — | — |
| 2025-12-08 | 10X Fund, L.P. | 10%+ Owner | Sell | — | — |
| 2025-12-04 | 10X Capital Management, LLC | 10%+ Owner | Sell | — | — |
| 2025-11-19 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| 2025-11-19 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-11-14 | Khurram Jamil | Chief Medical Officer | MIXED | — | — |
| 2025-11-12 | JAMES C CZIRR | 10%+ Owner | Sell | — | — |
| 2025-11-12 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-11-12 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| 2025-11-07 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-11-07 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| 2025-11-05 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-11-05 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| 2025-10-24 | JAMES C CZIRR | 10%+ Owner | Sell | — | — |
| 2025-09-15 | JOEL LEWIS | President and CEO | MIXED | — | — |
| 2025-09-15 | JACK W CALLICUTT | Chief Financial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 55,046,519 | — |
| — | Director | 11,758,091 | — |
| — | 10%+ Owner | 8,370,399 | — |
| — | 10%+ Owner | 5,802,207 | — |
| — | President and CEO | 778,260 | — |
| — | President & CEO | 207,333 | — |
| — | Director | 135,269 | — |
| — | Director | 67,682 | — |
| — | Director | 66,769 | — |
| — | Director | 60,614 | — |
| — | Director | 44,083 | — |
| — | Chief Medical Officer | 16,250 | — |
| — | Director | 13,581 | — |
| — | Chief Financial Officer | 7,614 | — |
| — | Director | 6,500 | — |
| — | Director | 1,083 | — |
| — | Director | 1,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GALT quote page; the site-wide leaderboard is on the insider transactions hub.